At ESMO 2014, Prof Johan F. Vansteenkiste summarises the results of the MAGRIT trial, a phase III trial which showed that MAGE-A3 cancer immunotherapy did not increase disease-free survival in patients with resected NSCLC.
Advertisement
[the_ad id="32629"]
Lung cancer vaccine MAGE-A3 does not improve disease-free survival in resected lung cancer
By Editor